252 related articles for article (PubMed ID: 11165136)
1. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract][Full Text] [Related]
2. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Takebayashi Y; Goldwasser F; Urasaki Y; Kohlhagen G; Pommier Y
Clin Cancer Res; 2001 Jan; 7(1):185-91. PubMed ID: 11205907
[TBL] [Abstract][Full Text] [Related]
3. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
6. Unique features of the mode of action of ET-743.
D'Incalci M; Erba E; Damia G; Galliera E; Carrassa L; Marchini S; Mantovani R; Tognon G; Fruscio R; Jimeno J; Faircloth GT
Oncologist; 2002; 7(3):210-6. PubMed ID: 12065793
[TBL] [Abstract][Full Text] [Related]
7. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
9. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.
Martinez EJ; Corey EJ; Owa T
Chem Biol; 2001 Dec; 8(12):1151-60. PubMed ID: 11755394
[TBL] [Abstract][Full Text] [Related]
11. [Ecteinascidin 743].
Lansiaux A; Bailly C
Bull Cancer; 1999 Feb; 86(2):139-41. PubMed ID: 10094523
[No Abstract] [Full Text] [Related]
12. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
Tavecchio M; Natoli C; Ubezio P; Erba E; D'Incalci M
Cell Prolif; 2007 Dec; 40(6):885-904. PubMed ID: 18021177
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
[TBL] [Abstract][Full Text] [Related]
14. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
15. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
16. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
[TBL] [Abstract][Full Text] [Related]
17. Role of homologous recombination in trabectedin-induced DNA damage.
Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G
Eur J Cancer; 2008 Mar; 44(4):609-18. PubMed ID: 18243687
[TBL] [Abstract][Full Text] [Related]
18. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
Hendriks HR; Fiebig HH; Giavazzi R; Langdon SP; Jimeno JM; Faircloth GT
Ann Oncol; 1999 Oct; 10(10):1233-40. PubMed ID: 10586342
[TBL] [Abstract][Full Text] [Related]
19. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
20. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.
Minuzzo M; Marchini S; Broggini M; Faircloth G; D'Incalci M; Mantovani R
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6780-4. PubMed ID: 10841573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
